AMWL
American Well Corporation
Medical - Healthcare Information Services
Market Cap$129M
5Y Perf.-98.7%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AMWL vs OPRX vs TDOC vs HCAT
Revenue, margins, valuation, and 5-year total return — side by side.
OPRX
OptimizeRx Corporation
Medical - Healthcare Information Services
Market Cap$124M
5Y Perf.-68.2%
TDOC
Teladoc Health, Inc.
Medical - Healthcare Information Services
Market Cap$1.26B
5Y Perf.-96.8%
HCAT
Health Catalyst, Inc.
Medical - Healthcare Information Services
Market Cap$113M
5Y Perf.-95.7%
AMWL vs OPRX vs TDOC vs HCAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AMWL | OPRX | TDOC | HCAT |
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $129M | $124M | $1.26B | $113M |
| Revenue (TTM) | $182M | $109M | $2.51B | $311M |
| Net Income (TTM) | $-88M | $5M | $-171M | $-178M |
| Gross Margin | 38.7% | 67.3% | 65.6% | 48.7% |
| Operating Margin | -50.6% | 10.7% | -7.6% | -51.7% |
| Forward P/E | — | 7.0x | — | 14.1x |
| Total Debt | $5M | $5M | $1.04B | $20M |
| Cash & Equiv. | $182M | $23M | $781M | $51M |
AMWL vs OPRX vs TDOC vs HCAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AMWL
OPRX
TDOC
HCAT
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| American Well Corpo… (AMWL) | 100 | 1.3 | -98.7% |
| OptimizeRx Corporat… (OPRX) | 100 | 31.8 | -68.2% |
| Teladoc Health, Inc. (TDOC) | 100 | 3.2 | -96.8% |
| Health Catalyst, In… (HCAT) | 100 | 4.3 | -95.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMWL vs OPRX vs TDOC vs HCAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OPRX leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. American Well Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AMWL
American Well Corporation
The Income Pick
AMWL is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 1.47
- Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
- Beta 1.47, current ratio 3.37x
- Beta 1.47 vs OPRX's 2.28, lower leverage
Best for: income & stability and sleep-well-at-night
OPRX
OptimizeRx Corporation
The Growth Play
OPRX carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
- 110.5% 10Y total return vs TDOC's -41.1%
- 18.8% revenue growth vs AMWL's -2.0%
- Lower P/E (7.0x vs 14.1x)
Best for: growth exposure and long-term compounding
TDOC
Teladoc Health, Inc.
The Specific-Use Pick
TDOC plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
HCAT
Health Catalyst, Inc.
The Value Angle
HCAT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OPRX | 18.8% revenue growth vs AMWL's -2.0% |
| Value | OPRX | Lower P/E (7.0x vs 14.1x) |
| Quality / Margins | OPRX | 4.7% margin vs HCAT's -57.2% |
| Stability / Safety | AMWL | Beta 1.47 vs OPRX's 2.28, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | AMWL | +14.3% vs HCAT's -59.9% |
| Efficiency (ROA) | OPRX | 3.0% ROA vs HCAT's -27.4%, ROIC 7.1% vs -32.9% |
AMWL vs OPRX vs TDOC vs HCAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
FY 2025
AMWL vs OPRX vs TDOC vs HCAT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOPRXLAGGINGHCAT
Who Leads Where
OPRX leads in 3 of 6 categories
AMWL leads 1 • TDOC leads 0 • HCAT leads 0 • 1 tied
Explore the data ↓HCATHealth Catalyst, Inc.
0leads
TDOCTeladoc Health, Inc.
0leads
AMWLAmerican Well Corpora…
1leads
OPRXOptimizeRx Corporation
3leads
6 Total Categories
CATEGORYLEADERvs AMWLvs TDOCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OPRX5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OPRX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
OPRX4/6
Risk & VolatilityBeta, volatility, and downside exposure
AMWL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
OPRX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC is the larger business by revenue, generating $2.5B annually — 23.0x OPRX's $109M. OPRX is the more profitable business, keeping 4.7% of every revenue dollar as net income compared to HCAT's -57.2%. On growth, OPRX holds the edge at -0.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $182M | $109M | $2.5B | $311M |
| EBITDAEarnings before interest/tax | -$59M | $16M | $42M | -$110M |
| Net IncomeAfter-tax profit | -$88M | $5M | -$171M | -$178M |
| Free Cash FlowCash after capex | -$42M | $12M | $251M | -$5M |
| Gross MarginGross profit ÷ Revenue | +38.7% | +67.3% | +65.6% | +48.7% |
| Operating MarginEBIT ÷ Revenue | -50.6% | +10.7% | -7.6% | -51.7% |
| Net MarginNet income ÷ Revenue | -48.2% | +4.7% | -6.8% | -57.2% |
| FCF MarginFCF ÷ Revenue | -22.9% | +10.6% | +10.0% | -1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -0.2% | -2.5% | -6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +44.5% | — | +32.1% | -2.9% |
OPRX leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — OPRX and TDOC and HCAT each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than TDOC's 15.1x.
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| Market CapShares × price | $129M | $124M | $1.3B | $113M |
| Enterprise ValueMkt cap + debt − cash | -$48M | $105M | $1.5B | $82M |
| Trailing P/EPrice ÷ TTM EPS | -1.30x | 24.56x | -6.11x | -0.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.04x | — | 14.15x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.55x | 15.13x | — |
| Price / SalesMarket cap ÷ Revenue | 0.52x | 1.13x | 0.50x | 0.36x |
| Price / BookPrice ÷ Book value/share | 0.50x | 0.98x | 0.89x | 0.45x |
| Price / FCFMarket cap ÷ FCF | — | 6.62x | 4.40x | — |
Evenly matched — OPRX and TDOC and HCAT each lead in 2 of 6 comparable metrics.
Profitability & Efficiency
OPRX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
OPRX delivers a 4.2% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-55 for HCAT. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs HCAT's 6/9, reflecting strong financial health.
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -33.5% | +4.2% | -12.4% | -54.7% |
| ROA (TTM)Return on assets | -25.1% | +3.0% | -5.9% | -27.4% |
| ROICReturn on invested capital | -95.1% | +7.1% | -11.5% | -32.9% |
| ROCEReturn on capital employed | -36.6% | +7.6% | -10.0% | -34.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.04x | 0.75x | 0.08x |
| Net DebtTotal debt minus cash | -$178M | -$19M | $259M | -$31M |
| Cash & Equiv.Liquid assets | $182M | $23M | $781M | $51M |
| Total DebtShort + long-term debt | $5M | $5M | $1.0B | $20M |
| Interest CoverageEBIT ÷ Interest expense | -239.18x | 1.26x | -8.76x | -4.79x |
OPRX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
OPRX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OPRX five years ago would be worth $1,266 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs HCAT's -59.9%. The 3-year compound annual growth rate (CAGR) favors OPRX at -23.0% vs HCAT's -49.2% — a key indicator of consistent wealth creation.
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +59.8% | -46.6% | -1.3% | -30.3% |
| 1-Year ReturnPast 12 months | +14.3% | -30.1% | +1.5% | -59.9% |
| 3-Year ReturnCumulative with dividends | -80.7% | -54.4% | -73.3% | -86.9% |
| 5-Year ReturnCumulative with dividends | -97.2% | -87.3% | -95.4% | -97.0% |
| 10-Year ReturnCumulative with dividends | -98.3% | +110.5% | -41.1% | -95.9% |
| CAGR (3Y)Annualised 3-year return | -42.2% | -23.0% | -35.6% | -49.2% |
OPRX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
AMWL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMWL is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs OPRX's 29.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 2.28x | 1.91x | 2.05x |
| 52-Week HighHighest price in past year | $9.15 | $22.25 | $9.77 | $5.06 |
| 52-Week LowLowest price in past year | $3.71 | $5.54 | $4.40 | $0.96 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +29.8% | +71.2% | +31.4% |
| RSI (14)Momentum oscillator 0–100 | 67.1 | 46.9 | 74.1 | 63.9 |
| Avg Volume (50D)Average daily shares traded | 59K | 476K | 5.5M | 720K |
AMWL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: OPRX as "Buy", TDOC as "Hold", HCAT as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 8.9% for TDOC (target: $8).
| Metric | AMWLAmerican Well Cor… | OPRXOptimizeRx Corpor… | TDOCTeladoc Health, I… | HCATHealth Catalyst, … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $17.00 | $7.58 | $2.50 |
| # AnalystsCovering analysts | — | 15 | 42 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% | 0.0% | +4.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
OPRX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMWL leads in 1 (Risk & Volatility). 1 tied.
Best OverallOptimizeRx Corporation (OPRX)Leads 3 of 6 categories
Loading custom metrics...
AMWL vs OPRX vs TDOC vs HCAT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMWL or OPRX or TDOC or HCAT a better buy right now?
For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.
8% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMWL or OPRX or TDOC or HCAT?
On forward P/E, OptimizeRx Corporation is actually cheaper at 7.
0x.
03Which is the better long-term investment — AMWL or OPRX or TDOC or HCAT?
Over the past 5 years, OptimizeRx Corporation (OPRX) delivered a total return of -87.
3%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMWL or OPRX or TDOC or HCAT?
By beta (market sensitivity over 5 years), American Well Corporation (AMWL) is the lower-risk stock at 1.
47β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 55% more volatile than AMWL relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AMWL or OPRX or TDOC or HCAT?
By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.
8% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMWL or OPRX or TDOC or HCAT?
OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.
7% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 10. 7% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMWL or OPRX or TDOC or HCAT more undervalued right now?
On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.
0x forward P/E versus 14. 1x for Health Catalyst, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.
08Which pays a better dividend — AMWL or OPRX or TDOC or HCAT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AMWL or OPRX or TDOC or HCAT better for a retirement portfolio?
For long-horizon retirement investors, American Well Corporation (AMWL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Health Catalyst, Inc. (HCAT) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMWL: -98. 3%, HCAT: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMWL and OPRX and TDOC and HCAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMWL is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; HCAT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AMWL: -100.0% · OPRX: -0.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.